Non Small Cell Lung Cancer Metastatic — Her2-positive Lung Cancer Treated With Dedicated Drug
Citation(s)
Phase II Trial of Trastuzumab in Combination With Pertuzumab in Pretreated Patients With Non-small Cell Lung Cancer (NSCLC) Harboring a Her2 Mutation and Receiving Docetaxel